BioStock: Pila Pharma enters agreement for toxicological studies
The journey towards phase IIb in type 2 diabetes continues for Malmö-based Pila Pharma. On Friday, the company announced that they had signed an agreement with the CRO ERBC to conduct three-month pre-clinical toxicology studies, a prerequisite to continue the clinical development.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se